[ENOX LETTERHEAD]



                                                                October 27, 2008

VIA EDGAR

Russell Mancuso, Branch Chief
Joseph McCann, Attorney
Securities and Exchange Commission
Division of Corporation Finance
100 F Street, NE
Mail Stop 6010
Washington, DC  20549

     Re: Enox Biopharma, Inc.
         Registration Statement on Form SB-2
         Filed February 4, 2008
         File No.  333-149028

Dear Messrs. Mancuso and McCann:

     Pursuant  to Rule 477  promulgated  under the  Securities  Act of 1933,  as
amended (the  "Securities  Act"),  Enox Biopharma,  Inc. (the "Company")  hereby
requests the  immediate  withdrawal of its  Registration  Statement on Form SB-2
(File No.  333-149028)  together with all exhibits  thereto  (collectively,  the
"Registration  Statement").  The Registration Statement was filed on February 4,
2008 and has not been declared effective.  No securities were sold in connection
with the offering contemplated in the Registration Statement. In accordance with
discussions  between  the  Commission  and the  Company's  counsel,  the Company
intends to promptly file a new  registration  statement on Form S-1,  which will
address the comment  received from the Staff on the Registration  Statement,  in
order to re-register the securities  covered by the  Registration  Statement and
register additional  securities.  Such registration  statement also will contain
updated disclosure.

     Should  you  have  any  questions,   please  contact  the   undersigned  at
604-603-1806  or David  Danovitch  or  Jaclyn  Amsel of  Gersten  Savage  LLP at
212-752-9700.

                                Very truly yours,


                                /s/ Yossef Av-Gay
                                -----------------------------
                                Prof. Yossef Av-Gay
                                President and CEO